Neely Ivgy-May, Ph.D. is a Pharmaceutical Drug Development Leader specializing in CNS, Women’s Health, and Uro-Oncology. Dr. Ivgy-May provides scientific and clinical expertise to Commercial Development and Business Development. She has a vast experience in interacting with the FDA and other regulatory authorities (EMA, PMDA) as clinical lead during pre-IND, End of Phase II, and pre- NDA meetings; Advisory Committee planning and participation. Dr. Ivgy-May is the founder and CEO of Ivgy-May Consulting Services. She worked close to 20 years in leading companies of the pharmaceutical industry: Schering Plough, Organon International and Merck Inc. Dr. Ivgy-May has a degree of Masters and Doctor of Philosophy from Columbia University College of Physician & Surgeons New York, NY.
David S. Siegel, M.D., Ph.D., Specializes in Hematology & Oncology and is Chief of Division for Multiple Myeloma (MM) at John Theurer Cancer Center in Hackensack University Medical Center (UMC). Dr. Siegel is one of the foremost authorities on Multiple Myeloma in the U.S.; he serves as a lead investigator in multi-center clinical trials for MM and led to the FDA’s fast-track approval of Kyprolis (carfilzomib) for relapsed Multiple Myeloma patients. Dr. Siegel’s research has been published in many leading medical journals, including Nature, New England Journal of Medicine, Blood and Journal of Clinical Oncology. He is a member of the Multiple Myeloma Research Consortium (MMRC) Steering Committee.
Jonathan E. Cohen MD, PhD. specializes in Cancer Research and Neuroscience at Hadassah Hebrew- University Medical Center. In his clinical work, Dr. Cohen focuses on General Oncology, while establishing his unique clinic of Malignant Melanoma and Cancer Immunotherapy with the objective of leveraging and extending novel therapies based on the Immune system for Melanoma as well as for other solid tumors. Dr. Cohen is a co-investigator on several multi-center clinical trials and presented his work in international conferences and in peer reviewed journals.
Professor Anwar Rayan is a co-Founder of Pepticom. Prof. Anwar Rayan is expert in the field of Bioinformatics, Chemoinformatics, drug design and discovery. During his work in the School of Pharmacy at the Hebrew University in Jerusalem and at FMP in Berlin, Professor. Rayan gained vast experience in the field of drug discovery and algorithms' development. He contributed to the development of novel tools for protein/peptide structure prediction, protein-protein docking, drug- likeness, Molecular Bioactivity Indexing Dr. Rayan is a Research Associate at the Hebrew University of Jerusalem and a Researcher at the QRC - Qasemi Research Center, Alkasemi College. He holds B.Sc. in Chemistry with distinction and earned a Ph.D. degree in Medicinal Chemistry from the Hebrew University of Jerusalem.